이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Inhibikase Therapeutics 미래 성장

Future 기준 확인 0/6

Inhibikase Therapeutics은 연간 수입과 매출이 각각 32.1%와 76.8% 증가할 것으로 예상되고 EPS는 연간 51.3%만큼 증가할 것으로 예상됩니다.

주요 정보

32.1%

수익 성장률

51.3%

EPS 성장률

Biotechs 수익 성장	24.1%
매출 성장률	76.8%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	21 May 2024

최근 미래 성장 업데이트

Recent updates

Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Apr 06

Inhibikase Therapeutics prices stock offering at $3

Jun 16

수익 및 매출 성장 예측

NasdaqCM:IKT - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	9	-25	-28	-21	2
12/31/2025	N/A	-26	-32	-20	2
12/31/2024	N/A	-19	-24	-18	2
3/31/2024	0	-19	-16	-16	N/A
12/31/2023	0	-19	-18	-18	N/A
9/30/2023	0	-19	-18	-18	N/A
6/30/2023	0	-19	-20	-20	N/A
3/31/2023	0	-18	-20	-19	N/A
12/31/2022	0	-18	-18	-17	N/A
9/30/2022	0	-19	-18	-18	N/A
6/30/2022	0	-19	-14	-14	N/A
3/31/2022	2	-17	-14	-14	N/A
12/31/2021	3	-15	-14	-14	N/A
9/30/2021	3	-11	-11	-11	N/A
6/30/2021	3	-7	-9	-9	N/A
3/31/2021	2	-5	-5	-5	N/A
12/31/2020	1	-3	-1	-1	N/A
9/30/2020	1	-2	0	0	N/A
6/30/2020	1	-3	0	0	N/A
3/31/2020	1	-5	0	0	N/A
12/31/2019	1	-6	0	0	N/A
9/30/2019	2	-7	1	1	N/A
3/31/2019	4	-4	0	0	N/A
12/31/2018	4	-2	1	1	N/A
9/30/2018	3	-1	0	0	N/A
3/31/2018	3	0	0	0	N/A
12/31/2017	2	0	N/A	0	N/A
12/31/2016	1	-1	N/A	0	N/A

애널리스트 미래 성장 예측

수입 대 저축률: IKT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: IKT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: IKT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: IKT 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: IKT 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: IKT 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Inhibikase Therapeutics 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Consensus revenue estimates increase by 44%

Consensus revenue estimates increase by 178%, EPS downgraded

Recent updates

Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.8 million.

First quarter 2024 earnings released: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023)

Inhibikase Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

New major risk - Market cap size

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Full year 2023 earnings: EPS misses analyst expectations

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.659255 million.

New major risk - Share price stability

Consensus revenue estimates increase by 44%

Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024

Inhibikase Therapeutics, Inc. Provides Update on Development Programs

Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Third quarter 2023 earnings released: US$0.86 loss per share (vs US$1.07 loss in 3Q 2022)

Inhibikase Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib

Consensus revenue estimates increase by 178%, EPS downgraded

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro

New major risk - Financial position

Second quarter 2023 earnings released: US$1.11 loss per share (vs US$1.10 loss in 2Q 2022)

Inhibikase Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Inhibikase Therapeutics Announces 1-For-6 Reverse Stock Split to Bring the Company into Compliance with Nasdaq's Minimum Bid Price Requirement

Inhibikase Therapeutics, Inc. Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Inhibikase Therapeutics, Inc. Initiates Medical and Patient Awareness Campaign for Its Phase 2 '201' Trial Evaluating It-148009 in Parkinson's Disease

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022)

Inhibikase Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 23, 2023

Inhibikase Therapeutics, Inc. announced that it expects to receive $4.199512 million in funding

Inhibikase Therapeutics Announces Publication Demonstrating Potential for C-Abl as A Key Therapeutic Target in Parkinson's Disease and Related Disorders

Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

Inhibikase Therapeutics, Inc. Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro

Inhibikase Therapeutics, Inc. Provides Update to FDA Clinical Hold of IkT-148009 Programs

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.18 loss in 3Q 2021)

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Inhibikase Therapeutics, Inc Announces FDA Clinical Hold on IkT-148009 Programs

High number of new and inexperienced directors

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. Announces Executive Changes

Inhibikase Therapeutics, Inc Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia

Inhibikase Therapeutics, Inc. Doses First Patient in Its Phase 2a '201' Clinical Trial of IKT-148009 to Treat Parkinson's Disease

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M

Inhibikase Therapeutics, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

Inhibikase Therapeutics Receives a Letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Inhibikase Therapeutics, Inc. Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review

First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.26 loss in 1Q 2021)

Inhibikase Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Full year 2021 earnings released: US$0.81 loss per share (vs US$0.35 loss in FY 2020)

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.082 loss in 3Q 2020)

Inhibikase Therapeutics, Inc. Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy

Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.052 loss in 2Q 2020)

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell Microcap Value Index

Inhibikase Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

Inhibikase Therapeutics prices stock offering at $3

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.067 loss in 1Q 2020)

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.067 loss in 1Q 2020)

CEO, President & Director exercised options and sold US$71k worth of stock

Full year 2020 earnings released: US$0.35 loss per share (vs US$0.70 loss in FY 2019)

Inhibikase Therapeutics, Inc. Announces Update on Phase 1 Clinical Trial of IkT-148009

Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from NASDAQ Composite Index

Inhibikase Therapeutics, Inc. to Appoint C. Warren Olanow as Interim Chief Medical Officer

Inhibikase Therapeutics, Inc. has completed an IPO in the amount of $18 million.